Tech Company Financing Transactions
Emvena Therapeutics Funding Round
Emvena Therapeutics closed a funding round on 11/4/2026. Investors included Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund).
Transaction Overview
Company Name
Announced On
11/4/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to advance its lead program toward investigational new drug (IND)-enabling studies and expand its placenta-targeted platform into additional maternal and fetal indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Philadelphia, PA Undisclosed
USA
Philadelphia, PA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Emvena Therapeutics is a biotechnology company developing placenta-targeted mRNA medicines for serious maternal and fetal conditions. Founded in 2026 based on research from the University of Pennsylvania, our lead program focuses on preeclampsia, a serious pregnancy complication with no approved therapy that treats the underlying disease. By restoring healthy blood vessel growth in the placenta, we aim to address the condition at its source and move beyond symptom management, with the potential to improve outcomes for both mother and baby.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Young Kwon
VP - R & D
Hannah Safford
Browse more venture capital transactions:
Prev: 11/4/2026: Pliant venture capital transaction
Next: 11/4/2026: Revolut venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs